Aevi Genomic Medicine (GNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,778 | -3,679 | -15,071 | -12,685 | -9,658 |
| Depreciation Amortization | 84 | 39 | 145 | 108 | 72 |
| Accounts receivable | -1,256 | -33 | 543 | 503 | -580 |
| Accounts payable and accrued liabilities | 24 | 74 | -26 | -133 | 15 |
| Other Working Capital | -1,280 | 286 | 829 | 609 | -472 |
| Other Operating Activity | 2,022 | 508 | 4,961 | 5,724 | 6,283 |
| Operating Cash Flow | $-6,184 | $-2,805 | $-8,619 | $-5,874 | $-4,340 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -142 | -37 | -63 | -54 | -45 |
| Other Investing Activity | 0 | 0 | 0 | 0 | -5 |
| Investing Cash Flow | $-142 | $-37 | $-63 | $-54 | $-50 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 28,874 | 28,874 | 10,118 | 9,932 | 8,435 |
| Financing Cash Flow | $28,874 | $28,874 | $10,118 | $9,932 | $8,435 |
| Beginning Cash Position | 6,431 | 6,431 | 4,995 | 4,995 | 4,995 |
| End Cash Position | 28,979 | 32,463 | 6,431 | 8,999 | 9,040 |
| Net Cash Flow | $22,548 | $26,032 | $1,436 | $4,004 | $4,045 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,184 | -2,805 | -8,619 | -5,874 | -4,340 |
| Capital Expenditure | -142 | -37 | -63 | -54 | -45 |
| Free Cash Flow | -6,326 | -2,842 | -8,682 | -5,928 | -4,385 |